Rein Therapeutics, Inc. (RNTX)
0.791
-0.01
(-1.12%)
USD |
NASDAQ |
Sep 21, 16:00
0.791
0.00 (0.00%)
After-Hours: 20:00
Rein Therapeutics Net Income (Quarterly) : -6.375M for June 30, 2026
Net Income (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -6.375M |
| March 31, 2026 | -5.838M |
| December 31, 2025 | -31.97M |
| September 30, 2025 | -5.581M |
| June 30, 2025 | -6.822M |
| March 31, 2025 | -5.501M |
| December 31, 2024 | -40.98M |
| September 30, 2024 | -5.847M |
| June 30, 2024 | -8.942M |
| March 31, 2024 | -7.113M |
| December 31, 2023 | -7.339M |
| September 30, 2023 | -1.827M |
| June 30, 2023 | -1.787M |
| March 31, 2023 | -4.779M |
| December 31, 2022 | -4.547M |
| September 30, 2022 | -6.368M |
| June 30, 2022 | -7.992M |
| March 31, 2022 | -8.422M |
| December 31, 2021 | -6.799M |
| September 30, 2021 | -6.704M |
| June 30, 2021 | -5.686M |
| March 31, 2021 | -6.975M |
| December 31, 2020 | -4.93M |
| Date | Value |
|---|---|
| September 30, 2020 | -5.023M |
| June 30, 2020 | -4.39M |
| March 31, 2020 | -6.748M |
| December 31, 2019 | -7.236M |
| September 30, 2019 | -7.749M |
| June 30, 2019 | -7.172M |
| March 31, 2019 | -7.213M |
| December 31, 2018 | -7.034M |
| September 30, 2018 | -7.434M |
| June 30, 2018 | -9.491M |
| March 31, 2018 | -7.588M |
| December 31, 2017 | -6.865M |
| September 30, 2017 | -6.259M |
| June 30, 2017 | -4.923M |
| March 31, 2017 | -4.557M |
| December 31, 2015 | -3.307M |
| September 30, 2015 | -3.201M |
| June 30, 2015 | 0.00 |
| March 31, 2015 | 0.00 |
| December 31, 2014 | -3.365M |
| September 30, 2014 | -3.343M |
| June 30, 2014 | 0.00 |
| March 31, 2014 | 0.00 |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 31.50M |
| Alnylam Pharmaceuticals, Inc. | 164.49M |
| Anika Therapeutics, Inc. | 3.309M |
| Savara, Inc. | -40.23M |
| Vericel Corp. | 2.206M |
Net Income (Quarterly) Related Metrics
| Total Expenses (Quarterly) | 6.375M |
| EPS Diluted (Quarterly) | -0.095 |
| Enterprise Value | 72.97M |
| Earnings Yield | -217.2% |
| Normalized Earnings Yield | -120.37 |